You can buy or sell Regeneron and other stocks, options, ETFs, and crypto commission-free!
Regeneron Pharmaceuticals, Inc. Common Stock, also called Regeneron, is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Read More It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
Tarrytown, New York
52 Week High
52 Week Low
Yahoo FinanceMar 18
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent
Regeneron Pharmaceuticals, Inc. REGN announced that the European Commission (EC) has approved a label expansion of its PCSK9 inhibitor, Praluent. The drug’s label has been expanded to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease (ASCVD) by lowering low-density lipoprotein cholesterol (LDL-C) levels as an adjunct to correction of other risk factors. The trial met its primary endpoint, showing that Praluent significantly reduced the relative risk of major adverse CV ...
Yahoo FinanceMar 18
Dermira Investors Get 100% One-Day Payoff a Year After Acne Flop
(Bloomberg) -- Investors who have hung on to their Dermira Inc. shares over the past year are finally starting to get paid for their patience. The stock surged as much as 118 percent on Monday, the most ever, after data showed that its experimental therapy for atopic dermatitis, or eczema, demonstrated results that were better than Regeneron Pharmaceuticals and Sanofi’s star drug Dupixent. The stock plunged 69 percent in March 2018 when the biotech company said its experimental acne drug failed in late-sta...
Markets InsiderMar 15
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
France, March 16, 2019 (GLOBE NEWSWIRE) -- Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome such as a heart attack Praluent is the only EU-approved PCSK9 inhibitor with cardiovascular outcomes data that showed an association with reduced death from any cause PARIS and TARRYTOWN, NY - March 15, 2...
Expected May 2, Pre-Market